Drawing for WILPAXA

USPTO serial 99879246

WILPAXA

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
HARDY LUDLOW, TARAH KIM
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).

Status 686: Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance.

Need help with WILPAXA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Lori Wolfe

Lori Wolfe Teva Pharmaceuticals USA, Inc.400 Interpace ParkwayBuilding AParsippany, NJ 07054

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and skin disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparationsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 3, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 3, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 28, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 1, 2026GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Oct 1, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 1, 2026XAECEXAMINER'S AMENDMENT ENTERED—
Oct 1, 2026GNEAEXAMINERS AMENDMENT E-MAILED—
Oct 1, 2026CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 24, 2026DOCKASSIGNED TO EXAMINER—
Jun 11, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 11, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 11, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance